These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34386974)

  • 1. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study.
    Lafaurie M; Maquet J; Baricault B; Ekstrand C; Christiansen CF; Linder M; Bahmanyar S; Nørgaard M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
    Br J Haematol; 2021 Nov; 195(3):456-465. PubMed ID: 34386974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study.
    Moulis G; Lapeyre-Mestre M; Montastruc JL; Sailler L
    Autoimmun Rev; 2015 Feb; 14(2):168-73. PubMed ID: 25461471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP.
    Rodeghiero F
    Br J Haematol; 2018 Apr; 181(2):183-195. PubMed ID: 29479668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Epidemiology and pharmacoepidemiology of immune thrombocytopenia].
    Moulis G; Lapeyre-Mestre M; Adoue D; Sailler L
    Rev Med Interne; 2017 Jul; 38(7):444-449. PubMed ID: 28131440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 8. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect.
    Moulis G; Lapeyre-Mestre M; Palmaro A; Sailler L
    J Thromb Haemost; 2017 Apr; 15(4):785-791. PubMed ID: 28078756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is ITP a thrombophilic disorder?
    Rodeghiero F
    Am J Hematol; 2016 Jan; 91(1):39-45. PubMed ID: 26547507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis in immune thrombocytopenia - current status and future perspectives.
    Swan D; Newland A; Rodeghiero F; Thachil J
    Br J Haematol; 2021 Sep; 194(5):822-834. PubMed ID: 33822358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients.
    Palandri F; Catani L; Auteri G; Bartoletti D; Fatica S; Fusco A; Bacchi Reggiani ML; Cavo M; Vianelli N
    Br J Haematol; 2019 Feb; 184(3):424-430. PubMed ID: 30408157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis.
    Tjepkema M; Amini S; Schipperus M
    Crit Rev Oncol Hematol; 2022 Mar; 171():103581. PubMed ID: 35007700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of ITP and AIHA in CVID: A systematic literature review].
    Lacombe V; Lozac'h P; Orvain C; Lavigne C; Miot C; Pellier I; Urbanski G
    Rev Med Interne; 2019 Aug; 40(8):491-500. PubMed ID: 31101329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.
    Ruggeri M; Tosetto A; Palandri F; Polverelli N; Mazzucconi MG; Santoro C; Gaidano G; Lunghi M; Zaja F; De Stefano V; Sartori R; Fazi P; Rodeghiero F;
    J Thromb Haemost; 2014 Aug; 12(8):1266-73. PubMed ID: 24942752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment.
    Mageau A; Terriou L; Ebbo M; Souchaud-Debouverie O; Orvain C; Graveleau J; Lega JC; Ruivard M; Viallard JF; Cheze S; Dossier A; Bonnotte B; Perlat A; Gobert D; Costedoat-Chalumeau N; Jeandel PY; Dernoncourt A; Michel M; Godeau B; Comont T
    Am J Hematol; 2022 Jan; 97(1):10-17. PubMed ID: 34661954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study.
    Pektaş G; Uncu İA; Dere Y; Öncü Ş; Kızılkaya MB; Sadi G; Pektaş MB
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064581
    [No Abstract]   [Full Text] [Related]  

  • 19. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoepidemiology of Immune Thrombocytopenia: protocols of FAITH and CARMEN studies.
    Moulis G; Sailler L; Adoue D; Lapeyre-Mestre M
    Therapie; 2014; 69(5):437-48. PubMed ID: 25285364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.